Skip to main content
Fuso Pharmaceutical Industries,Ltd. logo

Fuso Pharmaceutical Industries,Ltd. — Investor Relations & Filings

Ticker · 4538 ISIN · JP3823600006 T Manufacturing
Open in API
Filings indexed 65 across all filing types
Latest filing 2024-03-27 Legal Proceedings Report
Country JP Japan
Listing T 4538

About Fuso Pharmaceutical Industries,Ltd.

https://www.fuso-pharm.co.jp/en/

Fuso Pharmaceutical Industries, Ltd. is a company engaged in the development, manufacture, and sale of pharmaceuticals and medical equipment. The company's core business centers on providing essential medical products, with a primary focus on infusions, such as transfusion fluids, and solutions for artificial kidney dialysis. Its portfolio also includes a wide range of injectables for various therapeutic applications. In addition to supplying prescription drugs to medical institutions, Fuso Pharmaceutical Industries also develops and markets over-the-counter (OTC) medications. The company maintains a commitment to research and development, actively managing a drug pipeline and conducting clinical trials to introduce new treatments.

Recent filings

Filing Released Lang Actions
臨時報告書
Legal Proceedings Report Classification · 1% confidence The document header explicitly states the filing type as "【提出書類】 臨時報告書" (Filing Document: Extraordinary Report). The content details the submission to the Kanto Local Finance Bureau ("【提出先】 関東財務局長") on March 27, 2024, regarding a lawsuit where the plaintiff (Toray Corporation) filed an amendment to increase the damages claim. This structure—a formal report filed outside of regular periodic filings to disclose a significant, unexpected event (a major legal claim update)—aligns perfectly with the definition of a report concerning legal proceedings or a significant, non-routine disclosure. In the provided schema, "Legal Proceedings Report (Code: LTR)" is the most specific fit for updates on significant lawsuits. Although the Japanese term is 'Rinji Hokokusho' (Extraordinary Report), which often maps to 8-K filings in the US context, among the provided options, LTR captures the subject matter (litigation update) best. Given the document is the full report detailing the legal matter, not just an announcement of its publication, LTR is chosen over RPA or RNS.
2024-03-27 Japanese
訂正有価証券届出書（組込方式）
Capital/Financing Update Classification · 1% confidence The document is titled "有価証券届出書" (Registration Statement) and is submitted to the Kanto Local Finance Bureau ("関東財務局長"). It details the offering of new shares ("募集有価証券の種類：株式") through a self-share disposal ("自己株式処分") to an employee stock ownership plan ("扶桑薬品工業従業員持株会"). This structure—a formal filing detailing the terms, price, and recipient of a securities offering—is characteristic of a registration statement filed under the Financial Instruments and Exchange Act (Japan). While the content relates to capital changes (employee stock incentive plan), the document format and explicit title point directly to a registration statement, which in the context of US-equivalent filings (like S-1 or F-1) is best classified as a general regulatory filing or a specific capital/financing update. Given the explicit mention of '有価証券届出書' (Registration Statement), it is a core regulatory disclosure document. Since there is no direct equivalent for a Japanese Registration Statement among the provided codes, and it is a comprehensive filing detailing a capital change (share issuance/disposal), 'CAP' (Capital/Financing Update) is highly relevant, but 'RNS' (Regulatory Filings) serves as the best fit for formal, non-periodic regulatory disclosures that aren't 10-K/AR/ER/IR. However, because the document is fundamentally about the issuance of securities (a capital event), 'CAP' is a strong candidate. Reviewing the definitions, 'CAP' covers 'Updates on company fundraising, financing activities, or capital structure changes.' This document is the core filing for a capital structure change (employee stock issuance). I will classify it as CAP, as it is more specific than the general RNS fallback, despite being a formal registration document.
2024-02-13 Japanese
確認書
Regulatory Filings Classification · 1% confidence The document is a 'Confirmation Letter' (確認書) filed under the Financial Instruments and Exchange Act. It serves as an officer certification by the CEO of Fuso Pharmaceutical Industries, Ltd., confirming the accuracy of the contents of the third-quarter report. Per the 'Certification Rule', documents that are primarily officer certifications or attestations, even if they reference a specific report, should be classified as Regulatory Filings (RNS). Q3 101
2024-02-13 Japanese
四半期報告書－第101期第3四半期(2023/10/01－2023/12/31)
Interim / Quarterly Report Classification · 1% confidence The document is a 'Quarterly Report' (四半期報告書) filed with the Kanto Local Finance Bureau in Japan. It contains detailed financial statements, including the balance sheet and income statement for the third quarter of the 101st fiscal period (April 1, 2023, to December 31, 2023). It is a comprehensive financial report rather than an announcement or a summary, fitting the definition of an Interim/Quarterly Report (IR). 9M 2024
2024-02-13 Japanese
有価証券届出書（組込方式）
Share Issue/Capital Change Classification · 1% confidence The document is titled '有価証券届出書' (Securities Registration Statement) and is submitted to the Kanto Local Finance Bureau Director ('関東財務局長'). It details the proposed issuance of new shares ('新規発行株式') via a self-share disposal ('自己株式処分') to the Fuso Pharmaceutical Employees' Shareholding Association ('扶桑薬品工業従業員持株会') as part of an employee stock incentive plan (Restricted Stock Incentive System). This structure—a formal filing detailing the terms, price, and recipient of a planned issuance of securities—is characteristic of a registration statement filed under the Financial Instruments and Exchange Act (Japan). This specific type of filing, which registers the offering of securities, corresponds to the 'Securities Registration Statement' category, which is best mapped to the general '10-K' (Annual Report) or 'AR' (Audit Report) if a more specific Japanese equivalent isn't available, but given the context of a formal registration for a capital change/offering, it strongly aligns with a major regulatory filing related to securities issuance. In the provided list, '10-K' is for the Annual Report, and there isn't a direct code for a general Securities Registration Statement (like an S-1 or F-1 in the US context). However, the content is a comprehensive disclosure document about a capital transaction (share issuance/offering). Since it is a formal, detailed registration document for a securities offering, and not just a brief announcement (the document length is substantial), it is classified as a major regulatory filing. Given the options, and recognizing this is a comprehensive disclosure document for a capital event, it is closest in nature to a major periodic report or a specific offering document. Since it is a registration for an offering, and not a periodic report like 10-K, and it's too specific for RNS, I will check if any other code fits. The document describes a capital/financing activity (share issuance), but it is the registration document itself, not just an announcement. Based on the definitions, 'CAP' is for updates on financing activities, but this is the formal registration. Given the comprehensive nature and regulatory submission format, it is a core regulatory filing. Since there is no specific code for a Registration Statement, and it is not an Annual Report (10-K), Interim Report (IR), or Earnings Release (ER), the most appropriate classification among the choices for a comprehensive, formal regulatory disclosure document detailing a securities offering is often the general regulatory category or the category related to the subject matter. Since it is a formal filing detailing a capital change, and the document is extensive, I will classify it as a major regulatory filing that is not a standard periodic report. Given the options, and the focus on capital structure change via share issuance, 'CAP' (Capital/Financing Update) might seem relevant, but this is the formal registration document. I will default to the most comprehensive regulatory filing type available that isn't a standard periodic report, which is often 'RNS' (Regulatory Filings) when a specific code is missing, or look for the closest fit. Since it is a formal registration statement ('有価証券届出書'), it is a primary regulatory disclosure. I will select 'RNS' as the best fit for a non-standard, comprehensive regulatory filing not covered by 10-K, IR, or ER, as it is a formal submission to the financial authorities regarding securities.
2024-01-17 Japanese
確認書
Regulatory Filings Classification · 1% confidence The document is a 'Confirmation Letter' (確認書) filed under the Financial Instruments and Exchange Act. It serves as an officer certification by the CEO of Fuso Pharmaceutical Industries, Ltd., confirming the accuracy of the contents of the company's quarterly report. Per the 'CERTIFICATION RULE', documents that are primarily officer certifications or attestations, even if they reference a report, should be classified as Regulatory Filings (RNS). Q2 101
2023-11-10 Japanese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.